Free Republic

Researchers have published a case report that signifies a potential breakthrough in the treatment of an aggressive type of prostate cancer. The report centers around a 60-year-old Air Force Veteran diagnosed with stage four metastatic prostate cancer and the positive outcomes of being treated with trastuzumab deruxtecan (T-DXd), an antibody drug conjugate. The patient did not respond to multiple lines of therapy and experienced persistent tumor progression. As a last resort, the researchers tested for HER2 by immunohistochemistry, which came back positive and the patient was treated off-label in February 2024 with T-DXd. The antibody drug conjugate, which is FDA...

TALAPRO-2, a study led by Neeraj Agarwal, MD, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%. According to the National Cancer Institute, prostate cancer is the most common cancer and second leading cause of cancer death among men in the United States. Castration-resistant prostate cancer, or CRPC, is a late state of prostate cancer that continues to grow despite androgen blockade. TALAPRO-2 combines two oral medications, TALZENNA and XTANDI, to treat metastatic prostate cancer. The trial looks at the effectiveness of adding TALZENNA to the standard treatment of XTANDI,...

Stem cells and metastatic cancer: fatal attraction? It is widely hoped that neural stem cells will eventually be useful for replacing nerves damaged by degenerative diseases like Alzheimer disease and multiple sclerosis. But there may also be another use for such stem cells--delivering anti-cancer drugs to cancer cells. A Perspective article in PLoS Medic ine, by Professor Riccardo Fodde (Erasmus Medical Center, The Netherlands), discusses a new study in mice, published in the launch issue of PLoS ONE (www.plosone.org), that showed that neural stem cells could be used to help deliver anti-cancer drugs to metastatic cancer cells. One of the...

DUARTE, Calif. -- Patients with advanced cancer that has spread to many different sites often do not have many treatment options, since they would be unable to tolerate the doses of treatment they would need to kill the tumors.  Researchers at City of Hope and St. Jude Children's Research Hospital may have found a way to treat cancers that have spread throughout the body more effectively. They used modified neural stem cells to activate and concentrate chemotherapeutic drugs predominately at tumor sites, so that normal tissue surrounding the tumor and throughout the body remain relatively unharmed."This approach could significantly improve...